Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population

Completed

Conditions studied: Prostate Cancer

In brief

The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.

Key facts

Study ID

NCT02518698

Run by

Bayer

People needed

1163

Starts

2015-08-31

Expected to finish

2017-09-30

Last updated by the study team

2018-09-18

Who can join

Age: 55 and older, up to 88. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• First diagnosis for bone metastases for members diagnosed with prostate cancer found in the claims data during the identification period
• Members age ≥ 55 to 89 years at index
• Medicare members with medical and pharmacy coverage; and
• Continuously enrolled during the pre- and post-index periods.

You may not qualify if…

• Member with diagnosis of any other cancer (excluding melanoma (ICD-9 172.x) and other metastases (ICD-9 198.x)) before the index date; and
• Members age ≥ 89 years of age at index date

Where it is running

• Study site — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.